Mixed Findings on Renal Outcomes With DPP-4 Inhibitors in T2D Mixed Findings on Renal Outcomes With DPP-4 Inhibitors in T2D
Renal outcomes data from two large cardiovascular-outcomes trials with the type 2 diabetes drugs saxagliptin and sitagliptin, both DPP-4 inhibitors, hint at some kidney benefit with saxagliptin.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - November 4, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

EASD: Novel SGLT2 Drug Works in Triple Therapy (CME/CE)
(MedPage Today) -- Ertugliflozin improved T2D control atop metformin/sitagliptin (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - September 15, 2016 Category: Urology & Nephrology Source Type: news

Merck and Pfizer Announce Investigational Ertugliflozin Met Primary Endpoint of A1C Reduction When Added to Sitagliptin and Metformin in People with Type 2 Diabetes
Dateline City: KENILWORTH, N.J., and NEW YORK, N.Y.New Phase 3 Data Presented at the European Association for the Study of Diabetes Annual Meeting – Study Achieved Primary and All Key Secondary EndpointsKENILWORTH, N.J., and NEW YORK, N.Y. -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc. (NYSE: PFE) today announced that a Phase 3 study (VERTIS SITA2) of ertugliflozin, an investigational oral SGLT2 inhibitor for the treatment of patients with type 2 diabetes, met its primary endpoint.Language: Englishread more (Source: Merck.com - Research and Development News)
Source: Merck.com - Research and Development News - September 15, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news

Switching GLP-1 For DPP-4 Improves Net T2D Outcomes
(MedPage Today) -- Victoza bests Januvia for combo therapy on A1c, weight, hypoglycemia composite (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 13, 2016 Category: Cardiology Source Type: news

Januvia (Sitagliptin Phosphate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 8, 2016 Category: Drugs & Pharmacology Source Type: news

Merck Results Underscore Need To Go Big Or Go Home In Diabetes Market
Looking at the earnings posted by Merck & amp; Co. (MRK), I could not help but compare and contrast them with what Sanofi (SNY) said this morning. Like Sanofi had with Lantus, Merck has a mega-blockbuster with Januvia. Just as Lantus was getting long in the tooth and facing patent expiration so too is Januvia. The main difference is how each company planned for life beyond their respective mega-blockbusters. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - July 29, 2016 Category: Pharmaceuticals Authors: David Kliff Source Type: news

Sitagliptin anti-atherosclerotic effects may be inconsequential
Results of the PROLOGUE study show that the dipeptidyl peptidase-4 inhibitor sitagliptin has no greater effect than other antidiabetic medications on progression of carotid intima-media thickness. (Source: MedWire News)
Source: MedWire News - June 30, 2016 Category: Consumer Health News Tags: Diabetes Source Type: news

Harnessing The Gut-Brain Axis
Nancy Thornberry is the CEO of Kallyope. . Nancy was formerly Senior Vice President and Franchise Head, Diabetes and Endocrinology, Merck & Co. Inc. In this role she led discovery and clinical research in diabetes, osteoporosis, fertility and contraception. Prior to her role as Franchise Head, Nancy initiated and was a leader of Merck’s dipeptidyl peptidase 4 (DPP-4) project, which resulted in the discovery of JANUVIA® for the treatment of Type 2 diabetes. Among other notable scientific accomplishments is the identification of the first caspase, interleukin-1β converting enzyme (ICE/caspase-1). For her s...
Source: Forbes.com Healthcare News - June 28, 2016 Category: Pharmaceuticals Authors: Josh Wolfe Source Type: news

FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain
[8-28-2015] The U.S. Food and Drug Administration (FDA) is warning that the type 2 diabetes medicines sitagliptin, saxagliptin, linagliptin, and alogliptin may cause joint pain that can be severe and disabling. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 23, 2016 Category: Drugs & Pharmacology Source Type: news

Think Twice Before Prescribing DPP-4 Inhibitors for DiabetesThink Twice Before Prescribing DPP-4 Inhibitors for Diabetes
In this commentary, the author raises thought-provoking questions regarding the potential risks and benefits of using sitagliptin in high-risk patients with inadequately controlled type 2 diabetes. Evidence-Based Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 20, 2016 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Subdermal mini-pump with exenatide superior to sitagliptin in reducing HbA1c
NEW ORLEANS – The second trial involving a sub-dermal matchstick-size osmotic mini-pump that releases exenatide over 6 months in people who have poorly controlled type 2 diabetes achieved superior... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - June 12, 2016 Category: Endocrinology Source Type: news

Meet The Woman Who Launched A New Field Of Scientific Study
As a female chemical engineer, Frances Arnold was already a rarity. After all, only about 16 percent of chemical engineers are women. But now that she has become the first woman ever to win the prestigious Millennium Technology Prize — it was awarded in Helsinki, Finland, on May 24 — Arnold is truly one of a kind. And she knows that in addition to a big cash award (1 million euros, or about $1.3 million), the prize brings an opportunity to spotlight the gender gap in STEM (science, technology, engineering and math) careers and to be a role model for other women. "I hope that my getting this prize will highlight...
Source: Science - The Huffington Post - May 31, 2016 Category: Science Source Type: news

Sitagliptin No Help for Fatty Liver
(MedPage Today) -- But study supports use of MRI as non-invasive liver fat measure (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 17, 2016 Category: Cardiology Source Type: news

Diabetes drug found no better than placebo at treating nonalcoholic fatty liver disease
A randomised, double-blind, controlled trial of sitagliptin showed that the diabetes medication works no better than a pacebo in treating nonalcoholic fatty liver disease. Science Daily (Source: Society for Endocrinology)
Source: Society for Endocrinology - May 16, 2016 Category: Endocrinology Source Type: news

Diabetes drug, placebo work the same on fatty liver disease
Stephen FellerSAN DIEGO, May 12 (UPI) -- The diabetes drug Januvia was shown in a recent study to have the same effect as placebo against non-alcoholic fatty liver disease, researchers report. (Source: Health News - UPI.com)
Source: Health News - UPI.com - May 12, 2016 Category: Consumer Health News Source Type: news